| 1. |
Updated clinical guidelines and recommendations for the primary treatment of early breast cancer have been published by the International Consensus Panel |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume 421,
Issue &NA;,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 2. |
Escitalopram worth it for preventing SAD relapse |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume 421,
Issue &NA;,
2003,
Page 3-4
L Hunt,
Preview
|
|
摘要:
Social anxiety disorder (SAD) is a prevalent, chronic psychiatric disorder characterised by a high level of comorbidity. US costs associated with anxiety disorders, of which SAD is the most prevalent, are estimated at nearly $US47 billion per year. Escitalopram, a selective serotonin reuptake inhibitor (SSRI), demonstrates long-term efficacy and is well tolerated among patients with SAD, according to the results of a study presented at the 156th Annual Meeting of the American Psychiatric Association (APA) [San Francisco, California, US; May 2003].1A second study presented at the meeting concluded that escitalopram enhances quality of life (QoL), and appears to be cost effective, in the prevention of relapse in patients with SAD.2Both studies were supported by funding from H Lundbeck A/S.
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 3. |
Guidelines for antiretroviral therapy in adults, adolescents updated |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume 421,
Issue &NA;,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 4. |
Newer HCV treatments"reasonably cost effective" |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume 421,
Issue &NA;,
2003,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 5. |
Olanzapine vs risperidone costs among US Medicaid beneficiaries |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume 421,
Issue &NA;,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 6. |
Atypical antipsychotics: adverse effect profile linked to treatment costs |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume 421,
Issue &NA;,
2003,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 7. |
Drug costs determine therapy choice in newly-diagnosed diabetes |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume 421,
Issue &NA;,
2003,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 8. |
Generalist, cardiologist collaborative care improves outcomes in HF |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume 421,
Issue &NA;,
2003,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 9. |
The newly-formed, not-for-profit Drugs for Neglected Diseases Initiative (DNDi)*has announced plans to spend $US255 million to develop six or seven drugs |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume 421,
Issue &NA;,
2003,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 10. |
Generics access delayed by EU law |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume 421,
Issue &NA;,
2003,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
首页
Volume 421 issue &NA;